VSee Health, Inc. Stock Price, News & Analysis

VSee Health (NASDAQ:VSEE) executed a three-year platform services agreement to provide virtual urgent care and virtual behavioral health across a health system operating more than 100 hospitals, outpatient centers, and affiliated sites. The contract is volume-based and invoice-only with no upper limit on reimbursable services, linking revenue directly to utilization. Services commence January 1, 2026. The unnamed partner is the region's sole Level 1 Trauma Center and an academic health system with longstanding medical school affiliation and multiple national rankings, which VSee characterizes as a national blueprint for replication to other top-tier academic and safety-net systems.

VSee Health (Nasdaq:VSEE) reports rapid teleradiology expansion after a FedRAMP High approval on October 28, 2025. The company says it completed 100,000+ radiology reads in six months across 18 of 35 hospitals, with full rollout to the remaining sites by December 31.

Reported operational and financial highlights include a Q2 revenue jump of 98% YoY to $3.4M with 47% margins, a disclosed $10M+ Level 1 hospital contract, a stated 285% stock surge since the FedRAMP milestone, and claimed access to a $455B federal telehealth opportunity through 2030.

VSee (Nasdaq:VSEE) announced it received an Authority to Operate (ATO) at the FedRAMP High level from the U.S. Department of Health and Human Services on October 28, 2025. The authorization permits other federal agencies to use VSee where FedRAMP High is required.

The platform is positioned for secure telehealth with enterprise encryption, HIPAA compliance, HIE interoperability, hybrid workflows, and rapid multi-site activation. In July, VSee rapidly deployed a secure telemedicine bridge for HHS ASPR to keep the only hospital on St. Croix operational after a cyberattack, clearing over 250 backlogged radiology studies within days. VSee is also advancing AIMEE, a rural hospital transformation initiative.

VSee Health (NASDAQ:VSEE) announced record-setting revenue growth and the elimination of over $5 million in legacy SPAC debt on October 23, 2025. The company said this debt removal strengthens its balance sheet, bolsters creditor confidence, and helps ensure compliance with NASDAQ listing requirements. Management framed the move as positioning VSee Health for sustained long-term growth and noted shareholder support as a key factor in the milestone.

VSee Health (Nasdaq:VSEE) announced a multi-year teleradiology contract executed May 7, 2025, with service delivery beginning June 15, 2025, for a premier Level 1 hospital system.

The deal is projected to generate approximately $10 million in gross revenue over the next two years, with provisions for an additional $5M+ in potential revenue, and is described as set to double annual recurring revenue. Revenue recognition has begun and will appear in the company's upcoming Q3 10-Q. The release lists a quoted share price of $0.479 and market cap of $8,123,227.67 as of October 20, 2025.

VSee Health (Nasdaq:VSEE) reported Second Quarter 2025 results for the three months ended June 30, 2025, with revenue of $3.4 million, up 98% year-over-year and a rise in gross profit margin from 45% to 47%. The company reported improved operating cash use in the first six months of 2025 at $765,094 versus $2,594,214 a year earlier. Cash flow from financing for H1 2025 was $746,040 compared with $3,597,841 in H1 2024, and investing cash use was minimal at $15,466.

The company attributes strong revenue growth to the acquisition and integration of iDoc Telehealth, expanded customer relationships, and new services that improved margins, while noting integration challenges remain.

VSee Health (NASDAQ:VSEE) has received approval from Nasdaq to maintain its listing status, subject to specific conditions. The company must file its delayed Q1 and Q2 2025 quarterly reports by October 15, 2025, and demonstrate compliance with Nasdaq's Equity Rule by December 1, 2025.

The company is actively working with its auditors to complete and submit the required financial reports within the extension period granted by the Nasdaq Hearings Panel. Additionally, VSee Health has confirmed its commitment to addressing and meeting the net equity requirements within the specified timeframe.

VSee Health (Nasdaq:VSEE) announced significant expansion of its teleradiology services, having implemented 17 out of 25 planned hospital integrations by August 2025. The company secured contracts with a major vendor for 22 hospitals, with an additional 3 hospitals recently awarded, bringing the total expected annual recurring revenue (ARR) to approximately $3 million.

Following a successful pilot of 3 hospitals in May 2025, VSee rapidly expanded to 17 hospitals within three months. The company's teleradiology platform offers real-time interpretation of medical imaging, 24/7 coverage, and seamless integration with existing hospital systems, enabling remote radiologist consultations and improved diagnostic efficiency.

VSee Health (NASDAQ:VSEE) announced it is appealing a NASDAQ Staff Determination to delist its common stock from the Nasdaq Capital Market. The delisting notice was received on August 5th, 2025, citing non-compliance with filing requirements for the 2024 Annual Report and Q1 2025 Quarterly Report.

The company has requested a hearing before the Nasdaq Listing Qualifications Panel, which automatically stays the delisting for 15 days. VSee Health plans to request an extended stay pending the hearing. If the appeal is unsuccessful, the company's stock could move to trading on the OTC Bulletin Board.